Allogeneic CAR T-Cell Product Shows Early Promise for Patients With CD30+ Lymphomas
May 17, 2021

An off-the-shelf cellular therapy that combines Epstein Barr Virus–Specific T cells and a CD30-targeting chimeric antigen receptor product demonstrated safety and early efficacy in a group of patients with CD30-positive lymphomas.

Expert Commentary on The Product Profile of Belantamab Mafodotin
May 17, 2021

Kathryn Maples, PharmD, BCOP, discusses real-world implications of belantamab mafodotin in patients with pretreated multiple myeloma.

Immunotherapy as First-Line Treatment for Extensive-Stage SCLC
May 17, 2021

The rationale for adding an immunotherapy agent to frontline therapy for extensive-stage small cell lung cancer and considerations for patient selection.